NASDAQ:KRON - Kronos Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 264.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.89
▼ -0.11 (-1.10%)

This chart shows the closing price for KRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kronos Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRON

Analyst Price Target is $36.00
▲ +264.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kronos Bio in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 264.00% upside from the last price of $9.89.

This chart shows the closing price for KRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Kronos Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2021HC WainwrightBoost Price TargetBuy$35.00 ➝ $36.00High
10/20/2021CowenInitiated CoverageOutperformLow
6/24/2021HC WainwrightInitiated CoverageBuy$35.00High
11/3/2020CowenInitiated CoverageOutperformHigh
11/3/2020Jefferies Financial GroupInitiated CoverageBuy$36.00High
11/3/2020The Goldman Sachs GroupInitiated CoverageBuy$45.00High
11/3/2020Piper SandlerInitiated CoverageOverweight$50.00High
(Data available from 1/19/2017 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/21/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/20/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Kronos Bio logo
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $9.89
Low: $9.86
High: $10.58

50 Day Range

MA: $13.60
Low: $10.00
High: $17.50

52 Week Range

Now: $9.89
Low: $9.86
High: $33.39

Volume

179,331 shs

Average Volume

242,578 shs

Market Capitalization

$557.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Kronos Bio?

The following Wall Street sell-side analysts have issued research reports on Kronos Bio in the last year: Cowen Inc, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for KRON.

What is the current price target for Kronos Bio?

1 Wall Street analysts have set twelve-month price targets for Kronos Bio in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 260.0%. HC Wainwright has the highest price target set, predicting KRON will reach $36.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $36.00 for Kronos Bio in the next year.
View the latest price targets for KRON.

What is the current consensus analyst rating for Kronos Bio?

Kronos Bio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KRON will outperform the market and that investors should add to their positions of Kronos Bio.
View the latest ratings for KRON.

How do I contact Kronos Bio's investor relations team?

The company's listed phone number is 650-781-5200 and its investor relations email address is [email protected] The official website for Kronos Bio is kronosbio.com.